Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101216 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers
A Phase 1 study, sponsored by Cellceutix Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02101216 is a Phase 1 study that has completed, run by Cellceutix Corporation. The registered enrollment target is 18 participants.
The verdict
NCT02101216, a Phase 1 study, has completed, sponsored by Cellceutix Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Cellceutix Corporation has created a new chemical entity for the treatment of psoriasis, termed Prurisol™, which is an ester of abacavir. This first-in-human study of Prurisol (abacavir acetate) is being performed to evaluate the pharmacokinetics, safety and tolerance of a single oral doses of Prurisol administered to healthy volunteers and the bioequivalence to abacavir sulfate (Ziagen). This study will be followed by a 505(b)(2) Phase 2 trial in patients with moderate to severe plaque psoriasis.
Interventions
- DRUG Ziagen
- DRUG Prurisol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02101216
The ClinicalTrials.gov registry entry for NCT02101216 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellceutix Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ziagen is the first listed.
NCT02101216 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02101216 about?
NCT02101216 is a clinical study titled "Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers". Cellceutix Corporation has created a new chemical entity for the treatment of psoriasis, termed Prurisol™, which is an ester of abacavir. This first-in-human study of Prurisol (abacavir acetate) is being performed to evaluate the pharmacokinetics, safety and tolerance of a single oral doses of Pruri...
What is the current status of trial NCT02101216?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-03. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02101216?
The interventions under investigation include: Ziagen (DRUG), Prurisol (DRUG).
Who is sponsoring clinical trial NCT02101216?
This trial is sponsored by Cellceutix Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.